NYSEAMERICAN:LCTX Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis → A Silent Invasion of America (From The Freeport Society) (Ad) Free LCTX Stock Alerts $0.92 -0.01 (-1.08%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.91▼$0.9450-Day Range N/A52-Week Range$0.84▼$1.61Volume544,801 shsAverage Volume1.07 million shsMarket Capitalization$173.58 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Lineage Cell Therapeutics alerts: Email Address Lineage Cell Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside607.0% Upside$6.50 Price TargetShort InterestBearish6.49% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$10,500 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.31 out of 5 stars 3.5 Analyst's Opinion Consensus RatingLineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLineage Cell Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Lineage Cell Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.49% of the outstanding shares of Lineage Cell Therapeutics have been sold short.Short Interest Ratio / Days to CoverLineage Cell Therapeutics has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in Lineage Cell Therapeutics has recently decreased by 0.89%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLineage Cell Therapeutics does not currently pay a dividend.Dividend GrowthLineage Cell Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LCTX. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 2 people have searched for LCTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lineage Cell Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders28.10% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lineage Cell Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Lineage Cell Therapeutics are expected to remain at ($0.12) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lineage Cell Therapeutics is -6.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lineage Cell Therapeutics is -6.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLineage Cell Therapeutics has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s arrest is phase oneIn this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election… To get all the details, go here now. About Lineage Cell Therapeutics Stock (NYSEAMERICAN:LCTX)Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.Read More LCTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LCTX Stock News HeadlinesMay 29, 2024 | insidertrades.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) CEO Acquires $10,500.00 in StockMay 30, 2024 | businesswire.comLineage to Present at 2024 BIO International ConventionMay 26, 2024 | barrons.comLineage Cell Therapeutics Inc.May 21, 2024 | finance.yahoo.comLineage Announces Updates to 2nd Annual Spinal Cord Injury Investor SymposiumMay 14, 2024 | markets.businessinsider.comBuy Rating on Lineage Therapeutics Backed by Roche Collaboration and Solid FinancialsMay 10, 2024 | finance.yahoo.comQ1 2024 Lineage Cell Therapeutics Inc Earnings CallMay 10, 2024 | finance.yahoo.comLineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Projections Amidst Revenue DeclinesMay 10, 2024 | finance.yahoo.comLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | businesswire.comLineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | markets.businessinsider.comBuy Rating for Lineage Cell Therapeutics as OpRegen Shows Durable Benefits for GA PatientsMay 6, 2024 | markets.businessinsider.comMaintained Buy Rating for Lineage Cell Therapeutics on Robust Clinical Trial Results and Strong Partnership with RocheMay 6, 2024 | businesswire.comOpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation SummitMay 2, 2024 | businesswire.comLineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024April 30, 2024 | businesswire.comLineage Receives Grant From California Institute for Regenerative Medicine (CIRM)April 29, 2024 | businesswire.comLineage Announces Changes to Board of DirectorsApril 19, 2024 | finance.yahoo.com12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear ByApril 1, 2024 | finance.yahoo.comLineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate DevelopmentMarch 28, 2024 | msn.com5 Simple Wealth-Building Tips For This Generation's Forward-ThinkersMarch 19, 2024 | markets.businessinsider.comOptimistic Buy Rating for Lineage Cell Therapeutics Ahead of OpRegen Study Data ReleaseMarch 18, 2024 | seekingalpha.comPuma Biotechnology dips after dismissal of its suit was granted by a federal judgeMarch 18, 2024 | finance.yahoo.com15 Best Anti-Aging Foods for Youthful SkinMarch 18, 2024 | finance.yahoo.comLineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor SymposiumMarch 18, 2024 | businesswire.comLineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor SymposiumMarch 14, 2024 | finance.yahoo.comBillionaire Ken Fisher and Corporate Insiders Are Buying These 10 StocksMarch 13, 2024 | finance.yahoo.comRG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation SummitSee More Headlines Receive LCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSEAMERICAN:LCTX CUSIPN/A CIKN/A Webwww.lineagecell.com Phone(442) 287-8963Fax510-521-3389Employees68Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$7.00 Low Stock Price Target$6.00 Potential Upside/Downside+607.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,490,000.00 Net Margins-295.59% Pretax Margin-295.30% Return on Equity-34.92% Return on Assets-22.14% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.71 Sales & Book Value Annual Sales$8.94 million Price / Sales19.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book2.63Miscellaneous Outstanding Shares188,800,000Free Float135,746,000Market Cap$173.58 million OptionableNot Optionable Beta1.31 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Brian M. Culley M.A. (Age 53)M.B.A., CEO, President & Director Comp: $986.7kMs. Jill Ann Howe (Age 47)CFO & Principal Financial and Accounting Officer Comp: $587.4kMr. George A. Samuel III (Age 43)J.D., General Counsel & Company Secretary Comp: $554.51kIoana C. HoneDirector of Investor RelationsDr. Charlotte Hubbert Ph.D.Vice President of Corporate DevelopmentMs. Brandi L. Roberts CPA (Age 50)M.B.A., Consultant Comp: $407.45kMr. William Annett MBA (Age 70)President & CEO of OncoCyte Corporation Comp: $53.2kDr. Rami Skaliter Ph.D. (Age 66)Chief Executive Officer of Cell Cure Neurosciences Ms. Alexandra HernandezSenior Director of Finance & ControllerDr. Harold D. Waitz (Age 82)Vice President of Regulatory Affairs & Quality Control Comp: $90kMore ExecutivesKey CompetitorsTaysha Gene TherapiesNASDAQ:TSHACARGO TherapeuticsNASDAQ:CRGXREGENXBIONASDAQ:RGNXOsiris TherapeuticsOTCMKTS:OSIRExscientiaNASDAQ:EXAIView All CompetitorsInsiders & InstitutionsBrian M CulleyBought 10,000 shares on 5/24/2024Total: $10,500.00 ($1.05/share)Comerica BankBought 250,000 shares on 5/17/2024Ownership: 0.133%Price T Rowe Associates Inc. MDBought 70,418 shares on 5/15/2024Ownership: 0.085%Vanguard Group Inc.Sold 10,916 shares on 5/10/2024Ownership: 4.435%Fifth Third Wealth Advisors LLCBought 20,000 shares on 4/16/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions LCTX Stock Analysis - Frequently Asked Questions Should I buy or sell Lineage Cell Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lineage Cell Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LCTX shares. View LCTX analyst ratings or view top-rated stocks. What is Lineage Cell Therapeutics' stock price target for 2024? 2 brokerages have issued 12 month target prices for Lineage Cell Therapeutics' shares. Their LCTX share price targets range from $6.00 to $7.00. On average, they expect the company's share price to reach $6.50 in the next year. This suggests a possible upside of 607.0% from the stock's current price. View analysts price targets for LCTX or view top-rated stocks among Wall Street analysts. How have LCTX shares performed in 2024? Lineage Cell Therapeutics' stock was trading at $1.09 at the beginning of 2024. Since then, LCTX stock has decreased by 15.7% and is now trading at $0.9194. View the best growth stocks for 2024 here. How were Lineage Cell Therapeutics' earnings last quarter? Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.04). The firm earned $1.44 million during the quarter, compared to analyst estimates of $2.22 million. Lineage Cell Therapeutics had a negative trailing twelve-month return on equity of 34.92% and a negative net margin of 295.59%. What other stocks do shareholders of Lineage Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lineage Cell Therapeutics investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Enerplus (ERF), KushCo (KSHB) and Zosano Pharma (ZSAN). Who are Lineage Cell Therapeutics' major shareholders? Lineage Cell Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.44%), Comerica Bank (0.13%), Price T Rowe Associates Inc. MD (0.09%) and Fifth Third Wealth Advisors LLC (0.01%). Insiders that own company stock include Angus C Russell, Brian M Culley, Broadwood Partners, LP, Dipti Amin, Don M Bailey, Gary S Hogge and Michael H Mulroy. View institutional ownership trends. How do I buy shares of Lineage Cell Therapeutics? Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:LCTX) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredSilver Expected for Extreme Price ActionOur newest Silver Investing Guide reveals how savvy investors are capitalizing on silver's continued rise – PL...Colonial Metals | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lineage Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.